(Q43898674)

English

Does timing of cytoreductive nephrectomy impact patient survival with metastatic renal cell carcinoma in the tyrosine kinase inhibitor era? A multi-institutional study

scientific article published on 13 February 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Does timing of cytoreductive nephrectomy impact patient survival with metastatic renal cell carcinoma in the tyrosine kinase inhibitor era? A multi-institutional study (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

1 reference

based on heuristic

inferred from title

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

author name string

Sean P Stroup

1

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Omer A Raheem

2

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Kerrin L Palazzi

3

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Michael A Liss

4

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Reza Mehrazin

5

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Ryan P Kopp

6

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Nishant Patel

7

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Seth A Cohen

8

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Samuel K Park

9

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Anthony L Patterson

10

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Christopher J Kane

11

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Frederick Millard

12

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Ithaar H Derweesh

13

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

language of work or name

0 references

publication date

13 February 2013

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

81

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

805-811

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.10.054

7 January 2021

Renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.10.054

7 January 2021

EORTC-GU group expert opinion on metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.10.054

7 January 2021

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.10.054

7 January 2021

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.10.054

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.10.054

7 January 2021

Targeted therapy for metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.10.054

7 January 2021

Sunitinib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.10.054

7 January 2021

Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.10.054

7 January 2021

Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.10.054

7 January 2021

Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.10.054

7 January 2021

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.10.054

7 January 2021

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.10.054

7 January 2021

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.10.054

7 January 2021

Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.10.054

7 January 2021

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.10.054

7 January 2021

Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.10.054

7 January 2021

Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.10.054

7 January 2021

The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.10.054

7 January 2021

Nephron-Sparing Surgery for Renal Cell Carcinoma: Detailed Analysis of Complications Over a 15-Year Period

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.10.054

7 January 2021

Mechanisms of adverse effects of anti-VEGF therapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2012.10.054

7 January 2021

Identifiers

10.1016/J.UROLOGY.2012.10.054

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43898674&oldid=2104240021"